Genzyme Corp - Pharmaceuticals & Healthcare - Deals and Alliances Profile
- GDPH13D
- Pages: 45
- October 2018
- Total Views:1279
- Region : North America
- GlobalData
- Equity Research Report
Details
Summary
Genzyme Corp (Genzyme), a subsidiary of Sanofi, is a biotechnology company that develops specialty care treatments targeting rare diseases, oncology, immunology and multiple sclerosis. It offers products for the treatment of indications including various forms of cancer, mucopolysaccharidosis I, multiple sclerosis, Gaucher disease type 1, long-term enzyme replacement therapy, acute lymphoblastic leukemia, atopic dermatitis, management of uric acid levels, fabry disease, rheumatoid arthritis, Pompe disease, non-Hodgkin's lymphoma, multiple myleoma, gastric adenocarcinoma and squamous cell carcinoma, and kidney transplant acute rejection. The company has several more products in various stages of development. It operates a research and development lab and manufacturing plants in the US, Belgium and Ireland. The company has presence across the world. Genzyme is headquartered in Massachusetts, the US.
Genzyme Corp-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table Of Content
Scope
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Genzyme Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Genzyme Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Genzyme Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Genzyme Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Genzyme Corp, Medical Devices Deals, 2012 to YTD 2018 10
Genzyme Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Genzyme Corp, Pharmaceuticals & Healthcare, Deal Details 13
Asset Purchase 13
Genzyme Acquires Caprelsa from AstraZeneca 13
Genzyme Completes Acquisition Of Leukine Manufacturing Facility From Bayer HealthCare For USD 98.5 Million 14
Venture Financing 15
Edimer Pharma Secures USD18 Million in Series B Funding 15
Ultragenyx Pharma Raises USD 75 Million In Series B Financing 16
Partnerships 18
Alnylam Pharma Enters into Agreement with Sanofi Genzyme 18
Sanofi Genzyme Enters into Research Agreement with Johns Hopkins School of Medicine 19
Recursion Pharma Enters into Research Agreement with Genzyme 20
Ablynx Enters into Research Agreement with Genzyme 21
Voyager Therapeutics Enters into Development Agreement with Genzyme 22
Genzyme Enters into Co-Development Agreement with University of Florida and University of Pennsylvania 23
Charcot-Marie-Tooth Association Enters into Agreement with Genzyme to Discover Therapies for CMT1A 24
Genzyme Enters Into Research Agreement With Cleveland Clinic 25
Alnylam Pharma And Genzyme Enter Into Agreement For RNAi Therapeutics As Genetic Medicines 26
Alnylam Pharma And Genzyme Expands Co-Development Agreement For RNAi Therapeutics 28
Merger 29
Sanofi Japan and Genzyme Japan Merge 29
Licensing Agreements 30
Asklepios BioPharma Enters Into Licensing Agreement With Genzyme For Duplex Gene Therapy Vector Technology 30
Asklepios BioPharma Enters Into Licensing Agreement With Genzyme For Intra-Strand Base-Pairing Technology 31
Equity Offering 32
Alnylam Pharma Raises USD70.7 Million in Private Placement of Shares 32
KaloBios Pharma Completes IPO For USD 70 Million 33
Asset Transactions 36
Admedus Acquires Manufacturing Facility From Genzyme Australasia 36
Genzyme Corp-Key Competitors 37
Genzyme Corp-Key Employees 38
Genzyme Corp-Locations And Subsidiaries 39
Head Office 39
Other Locations & Subsidiaries 39
Joint Venture 41
Recent Developments 42
Clinical Trials 42
Apr 11, 2017: Sanofi Genzyme to present data on GLD52 (GZ402668) at AAN 42
Feb 14, 2017: Sanofi Initiates Phase 2 Clinical Trial to Evaluate Therapy for Genetic Form of Parkinson's Disease 43
Other Significant Developments 44
Mar 22, 2017: Sanofi Genzyme Extends Its Multiple Myeloma Journey Partners Program To Cities Nationwide To Help Improve Patient Outcomes Through Peer-to-Peer Education 44
Appendix 45
Methodology 45
About GlobalData 45
Contact Us 45
Disclaimer 45
List Of Figure
List of Figures
Genzyme Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Genzyme Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Genzyme Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Genzyme Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Genzyme Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Genzyme Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Genzyme Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Genzyme Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Genzyme Corp, Medical Devices Deals, 2012 to YTD 2018 10
List Of Table
List of Tables
Genzyme Corp, Pharmaceuticals & Healthcare, Key Facts 2
Genzyme Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Genzyme Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Genzyme Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Genzyme Corp, Deals By Therapy Area, 2012 to YTD 2018 9
Genzyme Corp, Medical Devices Deals, 2012 to YTD 2018 10
Genzyme Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Genzyme Acquires Caprelsa from AstraZeneca 13
Genzyme Completes Acquisition Of Leukine Manufacturing Facility From Bayer HealthCare For USD 98.5 Million 14
Edimer Pharma Secures USD18 Million in Series B Funding 15
Ultragenyx Pharma Raises USD 75 Million In Series B Financing 16
Alnylam Pharma Enters into Agreement with Sanofi Genzyme 18
Sanofi Genzyme Enters into Research Agreement with Johns Hopkins School of Medicine 19
Recursion Pharma Enters into Research Agreement with Genzyme 20
Ablynx Enters into Research Agreement with Genzyme 21
Voyager Therapeutics Enters into Development Agreement with Genzyme 22
Genzyme Enters into Co-Development Agreement with University of Florida and University of Pennsylvania 23
Charcot-Marie-Tooth Association Enters into Agreement with Genzyme to Discover Therapies for CMT1A 24
Genzyme Enters Into Research Agreement With Cleveland Clinic 25
Alnylam Pharma And Genzyme Enter Into Agreement For RNAi Therapeutics As Genetic Medicines 26
Alnylam Pharma And Genzyme Expands Co-Development Agreement For RNAi Therapeutics 28
Sanofi Japan and Genzyme Japan Merge 29
Asklepios BioPharma Enters Into Licensing Agreement With Genzyme For Duplex Gene Therapy Vector Technology 30
Asklepios BioPharma Enters Into Licensing Agreement With Genzyme For Intra-Strand Base-Pairing Technology 31
Alnylam Pharma Raises USD70.7 Million in Private Placement of Shares 32
KaloBios Pharma Completes IPO For USD 70 Million 33
Admedus Acquires Manufacturing Facility From Genzyme Australasia 36
Genzyme Corp, Key Competitors 37
Genzyme Corp, Key Employees 38
Genzyme Corp, Other Locations 39
Genzyme Corp, Subsidiaries 39
Genzyme Corp, Joint Venture 41
Licence Rights
Single User License:
Report can be used by individual purchaser only
Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office
Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company
Section Purchase
INQUIRE FOR COVID-19 IMPACT ANALYSIS
Products and Companies
Products
Genzyme Corp, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Company Profile
Company Profile Title
Summary
Genzyme Corp (Genzyme), a subsidiary of Sanofi, is a biotechnology company that develops specialty care treatments targeting rare diseases, oncology, immunology and multiple sclerosis. It offers products for the treatment of indications including various forms of cancer, mucopolysaccharidosis I, multiple sclerosis, Gaucher disease type 1, long-term enzyme replacement therapy, acute lymphoblastic leukemia, atopic dermatitis, management of uric acid levels, fabry disease, rheumatoid arthritis, Pompe disease, non-Hodgkin's lymphoma, multiple myleoma, gastric adenocarcinoma and squamous cell carcinoma, and kidney transplant acute rejection. The company has several more products in various stages of development. It operates a research and development lab and manufacturing plants in the US, Belgium and Ireland. The company has presence across the world. Genzyme is headquartered in Massachusetts, the US.
Genzyme Corp-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Scope
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Genzyme Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Genzyme Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Genzyme Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Genzyme Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Genzyme Corp, Medical Devices Deals, 2012 to YTD 2018 10
Genzyme Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Genzyme Corp, Pharmaceuticals & Healthcare, Deal Details 13
Asset Purchase 13
Genzyme Acquires Caprelsa from AstraZeneca 13
Genzyme Completes Acquisition Of Leukine Manufacturing Facility From Bayer HealthCare For USD 98.5 Million 14
Venture Financing 15
Edimer Pharma Secures USD18 Million in Series B Funding 15
Ultragenyx Pharma Raises USD 75 Million In Series B Financing 16
Partnerships 18
Alnylam Pharma Enters into Agreement with Sanofi Genzyme 18
Sanofi Genzyme Enters into Research Agreement with Johns Hopkins School of Medicine 19
Recursion Pharma Enters into Research Agreement with Genzyme 20
Ablynx Enters into Research Agreement with Genzyme 21
Voyager Therapeutics Enters into Development Agreement with Genzyme 22
Genzyme Enters into Co-Development Agreement with University of Florida and University of Pennsylvania 23
Charcot-Marie-Tooth Association Enters into Agreement with Genzyme to Discover Therapies for CMT1A 24
Genzyme Enters Into Research Agreement With Cleveland Clinic 25
Alnylam Pharma And Genzyme Enter Into Agreement For RNAi Therapeutics As Genetic Medicines 26
Alnylam Pharma And Genzyme Expands Co-Development Agreement For RNAi Therapeutics 28
Merger 29
Sanofi Japan and Genzyme Japan Merge 29
Licensing Agreements 30
Asklepios BioPharma Enters Into Licensing Agreement With Genzyme For Duplex Gene Therapy Vector Technology 30
Asklepios BioPharma Enters Into Licensing Agreement With Genzyme For Intra-Strand Base-Pairing Technology 31
Equity Offering 32
Alnylam Pharma Raises USD70.7 Million in Private Placement of Shares 32
KaloBios Pharma Completes IPO For USD 70 Million 33
Asset Transactions 36
Admedus Acquires Manufacturing Facility From Genzyme Australasia 36
Genzyme Corp-Key Competitors 37
Genzyme Corp-Key Employees 38
Genzyme Corp-Locations And Subsidiaries 39
Head Office 39
Other Locations & Subsidiaries 39
Joint Venture 41
Recent Developments 42
Clinical Trials 42
Apr 11, 2017: Sanofi Genzyme to present data on GLD52 (GZ402668) at AAN 42
Feb 14, 2017: Sanofi Initiates Phase 2 Clinical Trial to Evaluate Therapy for Genetic Form of Parkinson's Disease 43
Other Significant Developments 44
Mar 22, 2017: Sanofi Genzyme Extends Its Multiple Myeloma Journey Partners Program To Cities Nationwide To Help Improve Patient Outcomes Through Peer-to-Peer Education 44
Appendix 45
Methodology 45
About GlobalData 45
Contact Us 45
Disclaimer 45
List Of Figure
List of Figures
Genzyme Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Genzyme Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Genzyme Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Genzyme Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Genzyme Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Genzyme Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Genzyme Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Genzyme Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Genzyme Corp, Medical Devices Deals, 2012 to YTD 2018 10
List Of Table
List of Tables
Genzyme Corp, Pharmaceuticals & Healthcare, Key Facts 2
Genzyme Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Genzyme Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Genzyme Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Genzyme Corp, Deals By Therapy Area, 2012 to YTD 2018 9
Genzyme Corp, Medical Devices Deals, 2012 to YTD 2018 10
Genzyme Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Genzyme Acquires Caprelsa from AstraZeneca 13
Genzyme Completes Acquisition Of Leukine Manufacturing Facility From Bayer HealthCare For USD 98.5 Million 14
Edimer Pharma Secures USD18 Million in Series B Funding 15
Ultragenyx Pharma Raises USD 75 Million In Series B Financing 16
Alnylam Pharma Enters into Agreement with Sanofi Genzyme 18
Sanofi Genzyme Enters into Research Agreement with Johns Hopkins School of Medicine 19
Recursion Pharma Enters into Research Agreement with Genzyme 20
Ablynx Enters into Research Agreement with Genzyme 21
Voyager Therapeutics Enters into Development Agreement with Genzyme 22
Genzyme Enters into Co-Development Agreement with University of Florida and University of Pennsylvania 23
Charcot-Marie-Tooth Association Enters into Agreement with Genzyme to Discover Therapies for CMT1A 24
Genzyme Enters Into Research Agreement With Cleveland Clinic 25
Alnylam Pharma And Genzyme Enter Into Agreement For RNAi Therapeutics As Genetic Medicines 26
Alnylam Pharma And Genzyme Expands Co-Development Agreement For RNAi Therapeutics 28
Sanofi Japan and Genzyme Japan Merge 29
Asklepios BioPharma Enters Into Licensing Agreement With Genzyme For Duplex Gene Therapy Vector Technology 30
Asklepios BioPharma Enters Into Licensing Agreement With Genzyme For Intra-Strand Base-Pairing Technology 31
Alnylam Pharma Raises USD70.7 Million in Private Placement of Shares 32
KaloBios Pharma Completes IPO For USD 70 Million 33
Admedus Acquires Manufacturing Facility From Genzyme Australasia 36
Genzyme Corp, Key Competitors 37
Genzyme Corp, Key Employees 38
Genzyme Corp, Other Locations 39
Genzyme Corp, Subsidiaries 39
Genzyme Corp, Joint Venture 41
Single User License:
Report can be used by individual purchaser only
Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office
Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company
INQUIRE FOR COVID-19 IMPACT ANALYSIS
Products
Genzyme Corp, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
: +91 9015378249
Related Reports
Page 69 | 
May 2022
Page 76 | April 2022
Page 68 | March 2022
Page 78 | March 2022
Page 56 | October 2021